Immunity,
Journal Year:
2023,
Volume and Issue:
56(3), P. 669 - 686.e7
Published: Feb. 16, 2023
Pan-betacoronavirus
neutralizing
antibodies
may
hold
the
key
to
developing
broadly
protective
vaccines
against
novel
pandemic
coronaviruses
and
more
effectively
respond
SARS-CoV-2
variants.
The
emergence
of
Omicron
subvariants
illustrates
limitations
solely
targeting
receptor-binding
domain
(RBD)
spike
(S)
protein.
Here,
we
isolated
a
large
panel
(bnAbs)
from
recovered-vaccinated
donors,
which
targets
conserved
S2
region
in
betacoronavirus
fusion
machinery.
Select
bnAbs
showed
broad
vivo
protection
all
three
deadly
betacoronaviruses,
SARS-CoV-1,
SARS-CoV-2,
MERS-CoV,
have
spilled
over
into
humans
past
two
decades.
Structural
studies
these
delineated
molecular
basis
for
their
reactivity
revealed
common
antibody
features
targetable
by
vaccination
strategies.
These
provide
new
insights
opportunities
antibody-based
interventions
pan-betacoronavirus
vaccines.
Proceedings of the National Academy of Sciences,
Journal Year:
2021,
Volume and Issue:
118(19)
Published: April 23, 2021
Significance
Neutralizing
antibodies
are
important
for
immunity
against
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
and
as
therapeutics
the
prevention
treatment
of
COVID-19.
We
identified
high-affinity
nanobodies
SARS-CoV-2
receptor-binding
domain
found
that
nanobody
cocktails
consisting
two
noncompeting
were
able
to
block
ACE2
engagement
with
RBD
variants
present
in
human
populations
potently
neutralize
both
wild-type
N501Y
D614G
variant
at
low
concentrations.
Prophylactic
administration
reduced
viral
loads
mice
infected
virus,
showing
useful
prophylactic
agents
SARS-CoV-2.
Science Immunology,
Journal Year:
2022,
Volume and Issue:
7(73)
Published: May 12, 2022
Understanding
immune
responses
after
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
breakthrough
infection
will
facilitate
the
development
of
next-generation
vaccines.
Here,
we
profiled
spike
(S)–specific
B
cell
Omicron/BA.1
in
messenger
RNA–vaccinated
donors.
The
antibody
response
was
characterized
by
high
levels
somatic
hypermutation
and
a
bias
toward
recognition
ancestral
SARS-CoV-2
strains,
suggesting
early
activation
vaccine-induced
memory
cells.
BA.1
induced
shift
immunodominance
hierarchy
from
S2
subunit,
which
is
highly
conserved
across
variants
concern
(VOCs),
antigenically
variable
receptor
binding
domain
(RBD).
A
large
proportion
RBD-directed
neutralizing
antibodies
isolated
donors
displayed
convergent
sequence
features
broadly
recognized
VOCs.
Together,
these
findings
provide
insights
into
role
preexisting
immunity
shaping
to
heterologous
variant
exposure.
Immunity,
Journal Year:
2023,
Volume and Issue:
56(3), P. 669 - 686.e7
Published: Feb. 16, 2023
Pan-betacoronavirus
neutralizing
antibodies
may
hold
the
key
to
developing
broadly
protective
vaccines
against
novel
pandemic
coronaviruses
and
more
effectively
respond
SARS-CoV-2
variants.
The
emergence
of
Omicron
subvariants
illustrates
limitations
solely
targeting
receptor-binding
domain
(RBD)
spike
(S)
protein.
Here,
we
isolated
a
large
panel
(bnAbs)
from
recovered-vaccinated
donors,
which
targets
conserved
S2
region
in
betacoronavirus
fusion
machinery.
Select
bnAbs
showed
broad
vivo
protection
all
three
deadly
betacoronaviruses,
SARS-CoV-1,
SARS-CoV-2,
MERS-CoV,
have
spilled
over
into
humans
past
two
decades.
Structural
studies
these
delineated
molecular
basis
for
their
reactivity
revealed
common
antibody
features
targetable
by
vaccination
strategies.
These
provide
new
insights
opportunities
antibody-based
interventions
pan-betacoronavirus
vaccines.